排序方式: 共有48条查询结果,搜索用时 15 毫秒
21.
Ronald Boet Ho-Keung Ng Sekhar Kumta Leung-Cho Chan Kwok-Wing Chiu Wai-Sang Poon 《Journal of clinical neuroscience》2004,11(4):432-436
We wish to report a rare case of clear-cell meningioma in the lumbosacral region in a 34-year-old male patient who presented to us with lower back pain and leg pain. The management of the patient will be reported and histological appearance discussed. This rare tumour in a difficult anatomical position presents a challenge that requires management in a multidisciplinary fashion. 相似文献
22.
23.
24.
Glioblastoma multiforme (GBM), the most malignant type of glioma, is the most common primary brain neoplasm. Although comprehensive therapeutic measures are applied, the prognosis of GBM remains dismal with a median post-treatment survival of less than one year. Modern molecular genetics has demonstrated that abnormal alterations of tumor suppressor genes (TSGs) and oncogenes are the major mechanisms responsible for the initiation and progression of this malignant tumor. Identifying rela… 相似文献
25.
目的通过研究髓母细胞瘤与幕上原始神经外胚叶肿瘤(SPNET)中RASSF1A基因的甲基化改变,探讨颅内原始神经外胚叶肿瘤(PNET)的不同亚型中该基因的表遗传学差异及其意义。方法收集25例原发髓母细胞瘤,9例原发SPNET,3株髓母细胞瘤细胞系和2株SPNET细胞系。采用甲基化特异性聚合酶链反应(MSP)检测RASSF1A基因启动子区的甲基化状态。应用去甲基化试剂5-aza-2’deoxycytidine处理存在基因表达缺失的细胞系,探讨基因表达与甲基化之间的关系。结果100%(25/25)的原发髓母细胞瘤、6/9的原发SPNET及全部PNET细胞系中均检测到RASSFIA基因的甲基化。相反,该基因甲基化在全部正常组织(包括2例小脑,5例大脑)中均未检测到。并且,RASSF1A在SPNET中的甲基化率明显低于髓母细胞瘤(Fisher精确检验,P=0.014)。在经去甲基化试剂处理的PNET细胞中,该基因表达得以恢复,证明甲基化与该基因沉默相关。结论RASSF1A甲基化是肿瘤特异性的,RASSF1A甲基化与PNET的发生有一定关联,不同亚型的PNET之间RASSF1A基因的不同甲基化状态提示髓母细胞瘤和SPNET是表遗传学上存在差异的两类肿瘤。 相似文献
26.
27.
Farshad Nassiri Justin Z Wang Olivia Singh Shirin Karimi Tatyana Dalcourt Nazanin Ijad Neda Pirouzmand Ho-Keung Ng Andrea Saladino Bianca Pollo Francesco Dimeco Stephen Yip Andrew Gao Kenneth D Aldape Gelareh Zadeh The International Consortium on Meningiomas 《Neuro-oncology》2021,23(8):1282
BackgroundThere is a critical need for objective and reliable biomarkers of outcome in meningiomas beyond WHO classification. Loss of H3K27me3 has been reported as a prognostically unfavorable alteration in meningiomas. We sought to independently evaluate the reproducibility and prognostic value of H3K27me3 loss by immunohistochemistry (IHC) in a multicenter study.MethodsIHC staining for H3K27me3 and analyses of whole slides from 181 meningiomas across three centers was performed. Staining was analyzed by dichotomization into loss and retained immunoreactivity, and using a 3-tiered scoring system in 151 cases with clear staining. Associations of grouping with outcome were performed using Kaplan-Meier survival estimates.ResultsA total of 21 of 151 tumors (13.9%) demonstrated complete loss of H3K27me3 staining in tumor with retained endothelial staining. Overall, loss of H3K27me3 portended a worse outcome with shorter times to recurrence in our cohort, particularly for WHO grade 2 tumors which were enriched in our study. There were no differences in recurrence-free survival (RFS) for WHO grade 3 patients with retained vs loss of H3K27me3. Scoring by a 3-tiered system did not add further insights into the prognostic value of this H3K27me3 loss. Overall, loss of H3K27me3 was not independently associated with RFS after controlling for WHO grade, extent of resection, sex, age, and recurrence status of tumor on multivariable Cox regression analysis.ConclusionsLoss of H3K27me3 identifies a subset of WHO grade 2 and possibly WHO grade 1 meningiomas with increased recurrence risk. Pooled analyses of a larger cohort of samples with standardized reporting of clinical definitions and staining patterns are warranted. 相似文献
28.
Oncogenic role of microRNAs in brain tumors 总被引:1,自引:0,他引:1
Jesse Chung-sean Pang Wai Kei Kwok Zhongping Chen Ho-Keung Ng 《Acta neuropathologica》2009,117(6):599-611
29.
Wang HY Sun BY Zhu ZH Chang ET To KF Hwang JS Jiang H Kam MK Chen G Cheah SL Lee M Liu ZW Chen J Zhang JX Zhang HZ He JH Chen FL Zhu XD Huang MY Liao DZ Fu J Shao Q Cai MB Du ZM Yan LX Hu CF Ng HK Wee JT Qian CN Liu Q Ernberg I Ye W Adami HO Chan AT Zeng YX Shao JY 《Journal of clinical oncology》2011,29(34):4516-4525